Physician profile
Deepthi Thotakura
NPI 1710369160
$6,213.69
in general payments reported to CMS, 2019-2025
48 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.67 · 2020: $98.40 · 2021: $128 · 2022: $847 · 2023: $1,221 · 2024: $1,904 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869 · Long Term Medical Supply Or Device Loan: $2,132 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.10 |
| Long Term Medical Supply Or Device Loan | $2,132.36 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,587.78 | 2022-2025 | |
| Daiichi Sankyo INC. | $332.03 | 2022-2025 | Datroway, Enhertu |
| Astrazeneca Pharmaceuticals LP | $286.59 | 2022-2025 | Imfinzi, Calquence |
| Gilead Sciences, INC. | $243.96 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $234.08 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $174.28 | 2022-2025 | Opdivo |
| Celgene Corporation | $173.88 | 2022-2025 | Pomalyst, Reblozyl, Opdualag |
| Pfizer INC. | $167.11 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $143.14 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Sobi, INC | $140.04 | 2022-2023 | |
| Seagen INC. | $119.04 | 2021-2023 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $118.20 | 2023-2025 | |
| Pharmaessentia USA Corporation | $99.95 | 2023-2025 | Besremi |
| Array Biopharma INC | $97.80 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Astellas Pharma US INC | $88.40 | 2022-2024 | Padcev, Vyloy |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $71.51 | 2023-2024 | Sir-Spheres Microspheres |
| Genzyme Corporation | $70.07 | 2023-2025 | |
| Eisai INC. | $65.36 | 2023-2024 | |
| Puma Biotechnology, INC. | $63.65 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $63.17 | 2023-2024 | Zepzelca |
| Beigene USA, INC. | $62.26 | 2020 | |
| Incyte Corporation | $58.53 | 2021-2025 | Monjuvi, Jakafi |
| Tempus Ai, INC | $49.72 | 2024-2025 | Xt Cdx |
| Amgen INC. | $46.29 | 2022 | |
| Lilly USA, LLC | $44.16 | 2020-2025 | Verzenio, Jaypirca |
| Karyopharm Therapeutics INC. | $41.49 | 2024-2025 | Xpovio |
| Boston Scientific Corporation | $40.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.31 | 2024 | Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $39.92 | 2022-2023 | Somatuline Depot, Onivyde |
| Emd Serono, INC. | $37.53 | 2023-2024 | Bavencio |
| Abbvie INC. | $32.40 | 2023 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $31.75 | 2023 | Libtayo |
| Kite Pharma, INC. | $30.16 | 2022 | |
| Stemline Therapeutics INC. | $27.38 | 2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $26.61 | 2022 | |
| Deciphera Pharmaceuticals INC. | $25.02 | 2024 | Qinlock |
| Geron Corporation | $24.70 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $24.68 | 2024 | Ojjaara |
| Genmab U.S., INC. | $22.76 | 2024 | Epkinly |
| Shockwave Medical, INC | $22.68 | 2020 | |
| Rigel Pharmaceuticals, INC. | $22.21 | 2022 | |
| Tersera Therapeutics LLC | $20.23 | 2022 | |
| Cti Biopharma Corp. | $20.05 | 2023 | Vonjo |
| Genentech USA, INC. | $18.88 | 2023 | Lunsumio, Polivy |
| Janssen Pharmaceuticals, INC | $18.00 | 2021 | |
| Blue Earth Diagnostics | $16.24 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.02 | 2025 | Monoferric |
| Terumo Medical Corporation | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Thotakura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.